Free tool
FAERS Monitor: Semglee
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 210605 or its brand name (Semglee, Insulin Glargine). Reports on generic versions are filed under their own applications.
Reports
367
Serious
188
51% of reports
Hospitalization
104
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- device issue38
- nausea30
- product dose omission issue26
- product quality issue26
- diarrhoea24
- blood glucose increased21
- dyspnoea19
- drug ineffective17
- fatigue17
- headache17
- hypoglycaemia16
- pain16
- vomiting16
- asthenia13
- weight decreased13
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 21 |
| 2021 | 42 |
| 2022 | 41 |
| 2023 | 46 |
| 2024 | 75 |
| 2025 | 89 |
| 2026 | 53 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,792 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device issueSignal | 38 | 24.3 | 18.0 | 829 |
| hypoglycaemiaSignal | 16 | 18.9 | 11.7 | 254 |
| product quality issueSignal | 26 | 11.0 | 7.6 | 227 |
| blood glucose increasedSignal | 21 | 6.4 | 4.2 | 91 |
| product dose omission issueSignal | 26 | 5.1 | 3.5 | 82 |
| weight decreasedSignal | 13 | 2.7 | 1.6 | 12 |
| nauseaSignal | 30 | 2.2 | 1.5 | 19 |
| diarrhoeaSignal | 24 | 2.1 | 1.4 | 14 |
| asthenia | 13 | 2.0 | 1.2 | 5 |
| vomiting | 16 | 2.0 | 1.2 | 7 |
| dyspnoea | 19 | 1.9 | 1.2 | 8 |
| headache | 17 | 1.6 | 1.0 | 3 |
| pain | 16 | 1.5 | 0.9 | 2 |
| fatigue | 17 | 1.3 | 0.8 | 1 |
| drug ineffective | 17 | 0.7 | 0.5 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.